---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023217"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:01:44.622324+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics completes FX-322 Phase 2b enrollment; Q3 net loss $19.5M, cash $99.3M

## Summary
- Phase 2b study of FX-322 for SNHL enrolled 142 participants; primary endpoint readout expected Q1 2023.
- Second hearing restoration program FX-345 to begin Phase 1b in coming weeks; H2 2023 results expected.
- MS remyelination program advanced to IND-enabling studies; IND filing planned for H2 2023.
- Q3 2022 net loss $19.5M vs $25.2M in Q3 2021; R&D expenses $11.7M, down from $15.7M.
- Cash, equivalents and marketable securities $99.3M; expected to fund operations into 2024.

## SEC filing metadata
- accession: 0000950170-22-023217
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/0000950170-22-023217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/freq-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023217
- JSON: https://secwatch.observer/filing/0000950170-22-023217.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023217.txt

## Key facts
- Earnings Releases
  Korro Bio, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/0000950170-22-023217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.